Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Ralpha with a KD of 20.7 pM when binding to human IL-4Ralpha epitopes. Rademikibart does not bind to IL-4Ralpha from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research[1].
Molekulargewicht:
(145.36 kDa)
Reinheit:
99.13
CAS Nummer:
[2648260-80-2]
Target-Kategorie:
Interleukin Related
Anwendungsbeschreibung:
MCE Product type: Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten